İçeriğe Atlayın Skip to Content
TREN

Shaping the Future of Oncology

Current oncology practice is combined with treatment planned for the individual patient.

Every patient history is different, so every treatment plan is written for that person.

Appointments and Contact Cancer Types
Prof. Dr. H. Ibrahim Petekkaya with the clinical molecular oncology team
Prof. Dr. H. Ibrahim Petekkaya working in his consulting room
Prof. Dr. H. Ibrahim PetekkayaMedical oncologist · Egepol Hospital, Konak, Izmir

Who Prof. Dr. H. Ibrahim Petekkaya Is

Prof. Dr. H. Ibrahim Petekkaya is a medical oncologist who plans systemic treatment for adult cancers. He graduated from Atatürk University Faculty of Medicine in 2000, trained in internal medicine at Çukurova University (2003-2008) and completed his medical oncology fellowship at Hacettepe University (2010-2013).

He sees patients at Egepol Hospital (Güneşli Mah. 507 Sok. No:3, Konak, Izmir, Türkiye) and previously worked at Izmir Tınaztepe University. Treatment decisions follow current guidelines, the molecular features of the tumour and the patient's general condition together.

26Articles published in international peer-reviewed journals
2Congress abstract awards
2013Medical oncology fellowship, Hacettepe University
Profile, Publications and Awards

Which Cancers Are Treated

Systemic treatment is planned for the cancers listed below. Each page explains symptoms, diagnosis, staging, treatment options and genomic assessment in plain language.

All Cancer Types
Ultrasound examination with a probeBreast

Breast Cancer

Chemotherapy, hormone therapy, targeted treatment and immunotherapy according to stage and subtype.

HER2-PositiveTriple-Negative
Open the Page
Chest radiographLung

Lung Cancer

Treatment guided by molecular profiling in non-small cell and small cell lung cancer.

Open the Page
Computed tomography scannerDigestive

Gastrointestinal Cancers

Systemic treatment in colorectal, pancreatic and stomach cancer with MSI, HER2 and KRAS assessment.

ColorectalPancreaticStomach
Open the Page
Dermatoscopy of a skin lesionSkin

Skin Cancers

Immunotherapy and BRAF-targeted treatment in melanoma; systemic options in advanced basal cell carcinoma.

MelanomaBasal Cell Carcinoma
Open the Page
Ultrasound machine consoleGynaecological

Gynaecological Cancers

BRCA testing and PARP inhibitor assessment in ovarian cancer; systemic treatment after chemoradiotherapy in cervical cancer.

OvarianCervical
Open the Page
Brain MRI slicesBrain

Glioblastoma

Temozolomide after surgery and radiotherapy, with the plan guided by MGMT status.

Open the Page
Magnetic resonance imaging scannerSarcoma

Sarcomas

Systemic treatment is planned by subtype in soft tissue and bone sarcomas and in gastrointestinal stromal tumour (GIST).

Open the Page

From Your NGS Report to Personalised Cancer Treatment

Next-generation sequencing (NGS) and comprehensive genomic profiling (CGP) reports are reviewed by the molecular oncology and genetics team coordinated by Prof. Dr. H. Ibrahim Petekkaya, not for the genomic alterations alone but together with the diagnosis, the stage, previous treatments and the current clinical picture.

With 18 years of specialist practice and six years of molecular oncology work, the review sets out what each alteration means clinically, which targeted therapy and immunotherapy options follow from it, the mechanisms behind drug resistance and which clinical trials are a realistic match, all read against current evidence. The aim is not to list mutations but to turn molecular data into a treatment strategy that fits the patient and can be carried out.

The scope of a report review and how it proceeds are explained by the secretariat once you have applied; no prices are published on this site.

NGS Report Review RequestUpload your NGS genetic report and we will start the processMessage the Secretariat on WhatsAppAsk about the process
Targeted TherapyImmunotherapyResistance MechanismsClinical Trials
Meet the Molecular Oncology and Genetics Team

How Systemic Treatment Is Chosen

The method is chosen from the tumour type, its stage, its molecular features and the patient’s general condition together. In most plans the methods follow one another or are used in combination.

All Treatment Methods
Sample preparation with a pipette in the laboratoryTargeted

Targeted Therapy

These drugs act on a specific molecular target in the tumour, such as HER2, EGFR or BRAF. Genomic profiling of the tumour shows which drug is suitable.

Open the Page
Cell culture examination in the laboratoryImmunotherapy

Immunotherapy

These drugs release the brakes that stop immune cells recognising the tumour. PD-L1 level, MSI status and tumour mutational burden all affect the decision.

Open the Page
Intravenous drug administrationChemotherapy

Chemotherapy

Chemotherapy acts on rapidly dividing cells and is given alone or alongside other methods. Duration, dose and side effect management are planned from the stage and the general condition.

Open the Page

Patient Stories

There is hope behind every course of treatment.

With a team that stands beside patients medically and personally, these short films set out current approaches in cancer care, how treatment is managed day to day and what personalised treatment means in practice. The films are in Turkish.

Watch All the Films
Not the Illness — We WonYouTube Short in Turkish
Meet the TeamYouTube Short in Turkish
Personalised Treatment in CancerYouTube Short in Turkish

How the Assessment Runs

Four steps run from the first enquiry to a treatment plan. At each step the patient is told which documents are needed and what the decision rests on.

Patient Guide
1

Enquiry and Documents

When you write on WhatsApp the clinic asks for the pathology report, imaging reports and any previous treatment summary. The documents are reviewed before the consultation.

2

The Consultation

The consultation covers the diagnosis, the stage and the treatment options, and your questions are answered. It takes place at Egepol Hospital; for enquiries from abroad an initial review can be made on the documents.

3

Genomic Assessment

Where the tumour type and stage call for it, comprehensive genomic profiling or germline testing is arranged. Results are interpreted with the molecular oncology team and, if needed, discussed at the molecular tumour board.

4

Treatment Plan and Follow-Up

The plan is explained in writing, including duration, how treatment is given and how side effects are managed. Review intervals and a contact route are agreed for the whole course.

How Assessment Works Preparing for Your Appointment Second Opinion

Latest Articles

The questions patients ask most often, current guidelines and how to read a genomic report, written in plain language.

All Articles
Scientist working at a next generation sequencerDiagnosis and Treatment

How Many Chemotherapy Cycles Are Given

The number of cycles follows guideline protocols and depends on the cancer type, the stage, the aim of treatment and how well it is tolerated.

Read the Article
Sample preparation on a genetic testing instrumentPrecision Oncology

What a VUS Result Means on an NGS Report

A variant of uncertain significance is a gene change whose clinical meaning is not yet established. Treatment is not decided on it, and the classification can change over time.

Read the Article
Clinicians reviewing imaging resultsCurrent Oncology

Treatment Sequence in Metastatic Colorectal Cancer

Current guidance recommends RAS, BRAF V600E, MMR/MSI and HER2 testing at diagnosis, and first-line treatment is ordered from those results.

Read the Article

Appointments and Contact

Prof. Dr. H. Ibrahim Petekkaya sees patients at Egepol Hospital in Konak, Izmir. For an assessment or a second opinion you can write on WhatsApp or call the hospital switchboard. Sending your documents in advance makes the consultation more useful.

Contact Page and Directions Preparing for Your Appointment
Prof. Dr. H. Ibrahim Petekkaya and the clinical team at Egepol Hospital
Egepol Hospital, Güneşli Mah. 507 Sok. No:3, Konak, Izmir, Türkiye